Journal · Updated 2026-08-11
Eden Review 2026: The Widest Footprint, an In-House Pharmacy, and Gated Prices
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
Eden owns two superlatives in our database: the widest reported footprint (~fifty states) and the market's clearest vertical integration — Contigo Compounding, the 503A pharmacy Eden acquired in August 2025 and operates in-house. The trade sits on the price axis: tier-based subscription pricing largely revealed at intake, with our provider-stated records carrying figures around one ninety-eight for semaglutide and four-oh-eight for tirzepatide all-in — the semaglutide number mid-market, the tirzepatide number near the tracked ceiling. The integration is genuinely interesting (a named, checkable pharmacy is built into the corporate structure itself); the gating is genuinely limiting (a program whose prices need intake to state can't be ranked on them); and the review is the tension between those two sentences.
What owning the pharmacy actually changes
In-house compounding converts this site's hardest question — which pharmacy, and can you verify it? — into a structural given: the pharmacy is Contigo, the name is public, and the fifteen-minute verification (state licenses including your state's non-resident register, FDA compounding records, accreditation, certificate of analysis) runs against a fixed target rather than an intake-extracted one. It also plausibly delivers what Eden's materials claim: micro-titration flexibility, faster dose adjustments, supply-chain control. The honest counterweight: integration concentrates accountability as well as capability — prescriber, dispenser, and seller under one roof removes the independent-pharmacy check-and-balance the traditional model carries — which is why the COA request matters more here, not less, and why "we test everything" claims should arrive as documents.
The prices, the gate, and the verdict
Our provider-stated figures place Eden's semaglutide near two hundred (above the ninety-nine-to-one forty-nine value band, below the ceiling) and its tirzepatide around four hundred — brand-adjacent territory where LillyDirect's four forty-nine FDA-approved vials become the obvious cross-shop, per the brand-versus-compounded math. The gate compounds the problem: tier-varying, intake-revealed pricing keeps Eden's rows recorded-not-ranked under methodology §4, exactly like Yucca's — and unlike Yucca, Eden's structural transparency (a named in-house pharmacy!) makes the price opacity feel like an unforced error. The verdict follows: for a buyer in one of the states the flat-rate programs miss, or one who values integrated micro-titration enough to pay mid-to-upper-tier rates, Eden is the credible option its footprint implies — after extracting the all-in maintenance figure in writing at intake. For the price-first buyer, the gate is the answer: programs that state their number exist at half these figures, and stating the number is the market's cheapest trust signal — one Eden, of all programs, is structurally positioned to send.
Questions people ask
How much does Eden cost for GLP-1s?
Pricing is tier-based and largely revealed at intake; our provider-stated records carry roughly $198/month all-in for semaglutide and $408 for tirzepatide. The tirzepatide figure sits near brand territory — LillyDirect's FDA-approved $449 vials are the natural cross-shop — and the intake gate keeps Eden recorded-but-unranked in our price tables.
What is Contigo Compounding?
Eden's in-house 503A pharmacy, acquired in August 2025 — the market's clearest vertical integration. It makes the pharmacy name a structural given (verification runs against a fixed, public target) while concentrating prescriber, dispenser, and seller under one roof — which is why the certificate-of-analysis request matters more here, not less.
Is Eden available in my state?
Almost certainly: its reported footprint of roughly fifty states is the widest we track, which makes Eden the common fallback in states the flat-rate programs miss (including Henry Meds' nine exclusions). Confirm at intake as always — and extract the all-in maintenance price in writing while you're there.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.